Radiopharma · Built to order
Medical isotope supply security: Lu-177, Pb-212, Tb-161, Cu-64 and others
For a named isotope, how secure is supply: who makes it, from what feedstock, on which reactors or accelerators, and against what demand?
What you receive
- A written report that answers the questions agreed at scoping, with a clear verdict on each
- The read from the leaders running these businesses, gathered through our search work and attributed by role
- A data workbook with the underlying tables, so your team can filter, check and reuse the work
- A source register with the source and date behind each key fact
What can be in scope
- Capacity by route and producer, on announced, commissioned, approved and delivered tiers
- Feedstock and enriched target supply
- Reactor, accelerator and generator dependence
- Qualification and regulatory status by supplier
- Pipeline demand and the supply balance
For one named isotope: capacity by route and producer, feedstock, reactor or accelerator dependence, qualification status and demand from the pipeline. Built for a programme or portfolio that depends on that isotope arriving on time.
Common subjects are Lu-177 (carrier-added and no-carrier-added), Pb-212 and its Th-228 feedstock, Tb-161, Cu-64 and other therapeutic and diagnostic radionuclides.
Who commissions it
- Developers choosing or qualifying a supplier
- Investors assessing single-source risk behind a programme or company
- Producers and CDMOs reading competitors and customers
- Strategy teams deciding which isotope to build a platform around
The questions it answers
- Who produces the isotope, by which route, and how much of their stated capacity is actually delivered?
- Which feedstock does each route depend on, and how concentrated is that feedstock?
- Which reactors, accelerators or generators sit behind supply, and what happens when one is offline?
- Which producers are qualified for clinical or commercial supply, and which are still qualifying?
- How does demand from the pipeline compare with qualified supply over the next few years?
What you are buying access to
A proprietary intelligence base
Producers, facilities, pipelines, transactions, compensation and dated market signals across radiopharma, ADC, cell and gene therapy, CDMO and CRO, built and maintained by ProGen.
Access to the people who run it
Our executive search work puts us in conversation with the leaders of these businesses every week. Their read on the market goes into your answer.
Built around your decision
Scoped to the call in front of you: an investment, a partner, a supplier or a market. Every key fact sourced and dated.
How it works
Tell us your question
Choose an analysis below or describe your own. The more specific the decision, the sharper the scope.
Scope and quotation within one business day
We reply with the questions we will answer, what is in and out of scope, the timeline and a fixed quotation.
Your answer, built to stand up
A written report with a clear verdict, the read from the leaders in the space, a data workbook and a source register.
Request this analysis
Tell us the decision and the questions behind it. Within one business day you have the scope, the timeline and a fixed quotation.
Other analyses
- The Isotope Production MapEvery medical isotope producer, mapped by route and capacity. Refreshed quarterly.
- Ac-225 Supply and Demand OutlookWhen does Ac-225 stop being scarce, and who wins when it does?
- CDMO Committed Capacity AssessmentHow much CDMO capacity can you actually book, and who booked it first?
